Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opdivo delivers superior five-year survival results in renal cell carcinoma
Bristol-Myers Squibb’ Opdivo yields superior survival results in RCC in a five-year follow-up of the CheckMate -025 study. (Credit: Sue Adair/Commons.wikimedia.org)
Bristol-Myers Squibb’ Opdivo yields superior survival results in RCC in a five-year follow-up of the CheckMate -025 study. (Credit: Sue Adair/Commons.wikimedia.org)